For the transition period from ____________ to ____________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 Commission File Number: 001-12584 SYNTHETIC BIOLOGICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada ...

Synthetic Biologics, Inc. (SYN) Q4 2021 Earnings Conference Call March 16, 2022 4:30 PM ET CompanyParticipants Chris Calabrese - LifeSci Advisors, IR Steven Shallcross - Chief Executive Officer & Chief Financial Officer Manel Cascallo - General Director of VCN & European Operations Frank Tufaro - Head of Operations of VCN Conference Call Participants Jim Molloy - Alliance Global Partners Jason McCarthy - Maxim Group Michael Okunewitch - Maxim Group Operator Greetings and welcome to the Synthetic Biologics F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from to Commission File Number: 001-12584 SYNTHETIC BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 13-3808303 (State or Other Jurisdiction of ...

Synthetic Biologics, Inc. (SYN) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communications Steven Shallcross - Chief Executive and Financial Officer Michael Kaleko - Senior Vice President-Research and Development Vince Wacher - Head of Corporate and Product Development Conference Call Participants James Molloy - Alliance Global Partners Michael Okunewitch - Maxim Group Operator Good afternoon, and welcome to Synthetic Biologics’ 202 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-12584 SYNTHETIC BIOLOGICS, INC. (Exact name of Registrant as Specified in Its Charter) For the quarterly period ended September 30, 2021 Nev ...

Synthetic Biologics, Inc. (SYN) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Vincent Perrone – Director, Corporate Communication Steven Shallcross - Chief Executive and Financial Officer Michael Kaleko - Senior Vice President-Research and Development Vince Wacher - Head-Product and Corporate Development Conference Call Participants James Molloy - Alliance Global Partners Michael Okunewitch - Maxim Group Operator Good afternoon, and welcome to Synthetic Biologics’ 2021 Seco ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ____________ to ____________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR Commission File Number: 001-12584 SYNTHETIC BIOLOGICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 1 ...

Synthetic Biologics, Inc. (SYN) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Vincent Perrone – Director-Corporate Communication Steven Shallcross – Chief Executive and Financial Officer Michael Kaleko – Senior Vice President-Research and Development Vince Wacher – Head-Product and Corporate Development Conference Call Participants Michael Okunewitch – Maxim Group Jim Molloy – Alliance Global Partners Operator Good afternoon, and welcome to Synthetic Biologics 2021 First Quart ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-12584 SYNTHETIC BIOLOGICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 13-3808303 FORM 10-Q Securit ...

Synthetic Biologics, Inc. (SYN) Q4 2020 Earnings Conference Call March 4, 2021 4:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communication Steve Shallcross - Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary, Director Mike Kaleko - Senior Vice President Research and Development Vince Wacher - Head, Product and Corporate Development Conference Call Participants Jim Molloy - Alliance Global Partners Michael Okunewitch - Maxim Group Operator Good afternoon, and w ...